- Home
- ASND
ASND
Ascendis Pharma A/S
as 11-15-2024 4:00pm EST
Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
| Founded: | 2006 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 7.3B | IPO Year: | 2015 |
| Target Price: | $191.77 | AVG Volume (30 days): | 422.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $90.13 - $161.00 | Next Earning Date: | 11-14-2024 |
| Revenue: | $365,187,374 | Revenue Growth: | 115.54% |
| Revenue Growth (this year): | 10.3% | Revenue Growth (next year): | 90.02% |
Latest Ascendis Pharma A/S News
ASND Breaking Stock News: Dive into ASND Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Ascendis Pharma Q3 Loss Narrows, Revenue Rises
GlobeNewswire
3 days ago
Ascendis Pharma Reports Third Quarter 2024 Financial Results
GlobeNewswire
10 days ago
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
Simply Wall St.
11 days ago
High Growth Tech Stocks In The United States To Watch
Pharmaceutical Technology
12 days ago
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA
GuruFocus.com
12 days ago
Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology
TipRanks
12 days ago
Ascendis Pharma and Novo Nordisk Join Forces
TipRanks
12 days ago
Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform
Compare ASND vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ASND Ascendis Pharma A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.